dr. Sandra Van Lint
- ORCID iD
- 0000-0001-9767-5386
Show
Sort by
-
- Journal Article
- A1
- open access
Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
-
- Journal Article
- A1
- open access
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state
-
- Journal Article
- A1
- open access
Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials
-
- Journal Article
- A1
- open access
Dendritic cell-based immunotherapy in lung cancer
-
- Journal Article
- A1
- open access
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE
-
- Journal Article
- A1
- open access
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication
-
- Journal Article
- A1
- open access
mRNA in cancer immunotherapy : beyond a source of antigen
-
- Journal Article
- A1
- open access
The opposing effect of type I IFN on the T cell response by non-modified mRNA-lipoplex vaccines Is determined by the route of administration
-
- Journal Article
- A1
- open access
Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant
-
Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses